182 related articles for article (PubMed ID: 37294843)
21. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
[TBL] [Abstract][Full Text] [Related]
22. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
23. Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis.
MacPherson P; Webb EL; Kamchedzera W; Joekes E; Mjoli G; Lalloo DG; Divala TH; Choko AT; Burke RM; Maheswaran H; Pai M; Squire SB; Nliwasa M; Corbett EL
PLoS Med; 2021 Sep; 18(9):e1003752. PubMed ID: 34499665
[TBL] [Abstract][Full Text] [Related]
24. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
25. Trends in CD4 Count Testing, Retention in Pre-ART Care, and ART Initiation Rates over the First Decade of Expansion of HIV Services in Haiti.
Koenig SP; Bernard D; Dévieux JG; Atwood S; McNairy ML; Severe P; Marcelin A; Julma P; Apollon A; Pape JW
PLoS One; 2016; 11(2):e0146903. PubMed ID: 26901795
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
27. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.
Sinha S; Shekhar RC; Singh G; Shah N; Ahmad H; Kumar N; Sharma SK; Samantaray JC; Ranjan S; Ekka M; Sreenivas V; Mitsuyasu RT
BMC Infect Dis; 2012 Jul; 12():168. PubMed ID: 22846195
[TBL] [Abstract][Full Text] [Related]
28. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
29. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
Gopalan N; Santhanakrishnan RK; Palaniappan AN; Menon PA; Lakshman S; Chandrasekaran P; Sivaramakrishnan GN; Reddy D; Kannabiran BP; Agiboth HKK; Krishnamoorthy V; Rathinam S; Chockalingam C; Manoharan T; Ayyamperumal M; Jayanthi N; Satagopan K; Narayanan R; Krishnaraja R; Sathiyavelu S; Kesavamurthy B; Suresh C; Selvachitiram M; Arasan G; Susaimuthu S; Rathinam P; Angamuthu P; Jayabal L; Murali L; Ramachandran R; Tripathy SP; Swaminathan S
JAMA Intern Med; 2018 Apr; 178(4):485-493. PubMed ID: 29507938
[TBL] [Abstract][Full Text] [Related]
30. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Vibhagool A
J Infect; 2006 Mar; 52(3):188-94. PubMed ID: 15992932
[TBL] [Abstract][Full Text] [Related]
31. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP
PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041
[TBL] [Abstract][Full Text] [Related]
32. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
33. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
34. Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial.
Manabe YC; Worodria W; van Leth F; Mayanja-Kizza H; Traore AN; Ferro J; Pakker N; Frank M; Grobusch MP; Colebunders R; Cobelens F
Am J Trop Med Hyg; 2016 Dec; 95(6):1265-1271. PubMed ID: 27928077
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV-Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial.
Yende-Zuma N; Naidoo K
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):430-6. PubMed ID: 26990824
[TBL] [Abstract][Full Text] [Related]
37. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda.
Hermans SM; Castelnuovo B; Katabira C; Mbidde P; Lange JM; Hoepelman AI; Coutinho A; Manabe YC
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):e29-35. PubMed ID: 22395671
[TBL] [Abstract][Full Text] [Related]
38. The effect of engaging unpaid informal providers on case detection and treatment initiation rates for TB and HIV in rural Malawi (Triage Plus): A cluster randomised health system intervention trial.
Bello G; Faragher B; Sanudi L; Namakhoma I; Banda H; Malmborg R; Thomson R; Squire SB
PLoS One; 2017; 12(9):e0183312. PubMed ID: 28877245
[TBL] [Abstract][Full Text] [Related]
39. Integrating HIV care and treatment into tuberculosis clinics in Lusaka, Zambia: results from a before-after quasi-experimental study.
Herce ME; Morse J; Luhanga D; Harris J; Smith HJ; Besa S; Samungole G; Kancheya N; Muyoyeta M; Reid SE
BMC Infect Dis; 2018 Oct; 18(1):536. PubMed ID: 30367622
[TBL] [Abstract][Full Text] [Related]
40. Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all.
Van Rie A; Patel MR; Nana M; Vanden Driessche K; Tabala M; Yotebieng M; Behets F
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):e110-7. PubMed ID: 24091692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
